Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.

Brian Andrew Van Tine Angela C HirbePeter OppeltAshley E FrithRicha Rathore Joshua D MitchellFei WanShellie BerryMichele LandeauGeorge A HebertonJohn GorcsanPeter R HuntjensYoku SoyamaJustin M VaderJose A Alvarez-CardonaKathleen W Zhang Daniel J LenihanRonald J Krone

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

At interim analysis, dexrazoxane did not reduce PFS in patients with STS treated with doxorubicin. Involvement of cardio-oncologists is beneficial for the monitoring and safe use of high-dose anthracyclines in STS.See related commentary by Benjamin and Minotti, p. 3809.

Keyphrases

phase ii study
high dose
drug delivery
open label
cancer therapy
small cell lung cancer
locally advanced
low dose
randomized controlled trial
radiation therapy
placebo controlled
newly diagnosed
advanced cancer
early breast cancer